CN101437514B - C-fms激酶抑制剂 - Google Patents
C-fms激酶抑制剂 Download PDFInfo
- Publication number
- CN101437514B CN101437514B CN2005800435040A CN200580043504A CN101437514B CN 101437514 B CN101437514 B CN 101437514B CN 2005800435040 A CN2005800435040 A CN 2005800435040A CN 200580043504 A CN200580043504 A CN 200580043504A CN 101437514 B CN101437514 B CN 101437514B
- Authority
- CN
- China
- Prior art keywords
- cyano
- carboxylic acid
- phenyl
- imidazole
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(*)(C1)NCCC1=O Chemical compound *C(*)(C1)NCCC1=O 0.000 description 5
- MCQBMEPMNNDCIB-FLIBITNWSA-N C/C(/C1=CCCCC1)=C/NCc1ncc(C#N)[nH]1 Chemical compound C/C(/C1=CCCCC1)=C/NCc1ncc(C#N)[nH]1 MCQBMEPMNNDCIB-FLIBITNWSA-N 0.000 description 2
- VDTCHYWIGZTGOO-KHPPLWFESA-N CC/C(/[N+]([O-])=O)=C(\C=C)/C1=CCOCC1 Chemical compound CC/C(/[N+]([O-])=O)=C(\C=C)/C1=CCOCC1 VDTCHYWIGZTGOO-KHPPLWFESA-N 0.000 description 1
- PYVLUMLBLJZAQD-UHFFFAOYSA-N CCCCCCCC(C)N(CC1)CCC1c(cc1)cc(C2=CCCCC2)c1NC(c1nc(C#N)c[nH]1)=[U] Chemical compound CCCCCCCC(C)N(CC1)CCC1c(cc1)cc(C2=CCCCC2)c1NC(c1nc(C#N)c[nH]1)=[U] PYVLUMLBLJZAQD-UHFFFAOYSA-N 0.000 description 1
- HUBUCDDYGXGAHC-UHFFFAOYSA-N CCN(CCN(C)C)c(cc1C2=CCCCC2)ccc1[N+]([O-])=O Chemical compound CCN(CCN(C)C)c(cc1C2=CCCCC2)ccc1[N+]([O-])=O HUBUCDDYGXGAHC-UHFFFAOYSA-N 0.000 description 1
- NWVGXXPWOYZODV-UHFFFAOYSA-N N#Cc1c[nH]cn1 Chemical compound N#Cc1c[nH]cn1 NWVGXXPWOYZODV-UHFFFAOYSA-N 0.000 description 1
- XTAIZYTUBDTRFK-UHFFFAOYSA-N Nc(ccc(C(CC1)CCS1(=N)=O)c1)c1I Chemical compound Nc(ccc(C(CC1)CCS1(=N)=O)c1)c1I XTAIZYTUBDTRFK-UHFFFAOYSA-N 0.000 description 1
- OHFPIBZSFJMBPA-UHFFFAOYSA-N OCCNCCN(CC1)CCC1c(cc1)cc(C2=CCCCC2)c1NC(c1ncc[nH]1)=O Chemical compound OCCNCCN(CC1)CCC1c(cc1)cc(C2=CCCCC2)c1NC(c1ncc[nH]1)=O OHFPIBZSFJMBPA-UHFFFAOYSA-N 0.000 description 1
- GJYJDYXPUHRJLS-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1C(CC1)=CCS1(=O)=O)=O Chemical compound [O-][N+](c(cc1)ccc1C(CC1)=CCS1(=O)=O)=O GJYJDYXPUHRJLS-UHFFFAOYSA-N 0.000 description 1
- JGOCTECQSPZHFX-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1C1=CCSCC1)=O Chemical compound [O-][N+](c(cc1)ccc1C1=CCSCC1)=O JGOCTECQSPZHFX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62121104P | 2004-10-22 | 2004-10-22 | |
| US60/621,211 | 2004-10-22 | ||
| PCT/US2005/037868 WO2006047277A2 (en) | 2004-10-22 | 2005-10-20 | Inhibitors of c-fms kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101437514A CN101437514A (zh) | 2009-05-20 |
| CN101437514B true CN101437514B (zh) | 2012-04-25 |
Family
ID=36228272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800435040A Expired - Fee Related CN101437514B (zh) | 2004-10-22 | 2005-10-20 | C-fms激酶抑制剂 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1807077B1 (https=) |
| JP (1) | JP5046950B2 (https=) |
| KR (1) | KR101273434B1 (https=) |
| CN (1) | CN101437514B (https=) |
| AU (1) | AU2005299837A1 (https=) |
| BR (1) | BRPI0516947A (https=) |
| CA (1) | CA2585053C (https=) |
| DK (1) | DK1807077T3 (https=) |
| EA (1) | EA013250B1 (https=) |
| ES (1) | ES2611604T3 (https=) |
| HU (1) | HUE033089T2 (https=) |
| MX (1) | MX2007004784A (https=) |
| NO (1) | NO339555B1 (https=) |
| PL (1) | PL1807077T3 (https=) |
| PT (1) | PT1807077T (https=) |
| UA (1) | UA88648C2 (https=) |
| WO (1) | WO2006047277A2 (https=) |
| ZA (1) | ZA200704106B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7427683B2 (en) | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
| US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
| US7429603B2 (en) | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| WO2006047504A1 (en) * | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Aromatic amides as inhibitors of c-fms kinase |
| NZ561613A (en) | 2005-02-18 | 2010-12-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| US20080269214A1 (en) * | 2005-03-04 | 2008-10-30 | Astrazeneca Ab | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors |
| WO2006124865A2 (en) * | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
| WO2006130493A2 (en) | 2005-05-31 | 2006-12-07 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| US20070004660A1 (en) * | 2005-06-10 | 2007-01-04 | Baumann Christian A | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
| US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| KR101443651B1 (ko) * | 2005-10-18 | 2014-09-23 | 얀센 파마슈티카 엔.브이. | Ｆｌｔ-3 키나제의 억제 방법 |
| BRPI0710548B8 (pt) | 2006-04-20 | 2021-05-25 | Janssen Pharmaceutica Nv | inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica |
| US8697716B2 (en) * | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| JP2009534380A (ja) * | 2006-04-20 | 2009-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼインヒビター |
| EA016611B1 (ru) * | 2006-04-20 | 2012-06-29 | Янссен Фармацевтика Н.В. | Способ лечения мастоцитоза |
| NZ572073A (en) * | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
| ES2536406T3 (es) | 2007-06-08 | 2015-05-25 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| AU2008258560C1 (en) | 2007-06-08 | 2014-04-10 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| ES2558152T3 (es) | 2007-06-08 | 2016-02-02 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| AU2013203813B2 (en) * | 2007-10-17 | 2014-07-31 | Janssen Pharmaceutica, N.V. | Inhibitors of C-FMS kinase |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| AU2008318854A1 (en) * | 2007-11-02 | 2009-05-07 | Janssen Pharmaceutica, N.V. | Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| ES2617619T3 (es) | 2008-06-05 | 2017-06-19 | Janssen Pharmaceutica, N.V. | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR |
| WO2011149841A1 (en) | 2010-05-25 | 2011-12-01 | Janssen Pharmaceutica Nv | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS |
| CA2865511A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| IN2015DN00659A (https=) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
| JP6290884B2 (ja) | 2012-08-07 | 2018-03-07 | ヤンセン ファーマシューティカ エヌ．ベー． | ｃ−ＦＭＳキナーゼ阻害剤の調製プロセス |
| WO2014041106A1 (en) * | 2012-09-17 | 2014-03-20 | F. Hoffmann-La Roche Ag | Triazole carboxamide derivatives |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103804349A (zh) * | 2012-11-01 | 2014-05-21 | 杨子娇 | 一类治疗青光眼的化合物及其用途 |
| CN104370880A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
| CN104370882A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类降低眼压的化合物及其制备方法和用途 |
| CN104370881A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类具有神经保护作用的化合物及其制备方法和用途 |
| WO2014151258A1 (en) * | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Substituted pyridine derivatives useful as c-fms kinase inhibitors |
| EA030067B1 (ru) | 2013-07-22 | 2018-06-29 | Идорсиа Фармасьютиклз Лтд | Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| JP6337218B2 (ja) | 2015-01-15 | 2018-06-06 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｃｘｃｒ３受容体調節剤としてのヒドロキシアルキル−ピペラジン誘導体 |
| JP7012822B2 (ja) * | 2017-08-10 | 2022-02-14 | 中国科学院上海薬物研究所 | フタラジノン系化合物、その製造方法、医薬組成物及びその使用 |
| US10930064B2 (en) | 2018-02-08 | 2021-02-23 | Covidien Lp | Imaging reconstruction system and method |
| AU2019407650B2 (en) | 2018-12-17 | 2022-10-27 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
| WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
| WO2024254440A1 (en) * | 2023-06-09 | 2024-12-12 | Modulo Bio, Inc. | 5-cyano-1h-imidazole-2-carboxamide compounds as csf1r inhibitors |
| WO2026010948A1 (en) | 2024-07-01 | 2026-01-08 | Otsuka America Pharmaceutical, Inc. | Compounds useful for the treatment of disorders and methods related thereto |
| WO2026030444A1 (en) | 2024-07-30 | 2026-02-05 | Otsuka America Pharmaceutical, Inc | Compounds useful for the treatment of disorders and methods related thereto |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| AU747427B2 (en) * | 1998-07-10 | 2002-05-16 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| DK1140938T3 (da) * | 1999-01-11 | 2003-12-22 | Univ Princeton | Højaffinitetsinhibitorer for målvalidering og anvendelser heraf |
| CA2394727A1 (en) | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| DE60317198T2 (de) * | 2002-05-23 | 2008-12-04 | Cytopia Research Pty. Ltd., Richmond | Proteinkinaseinhibitoren |
| KR20120032574A (ko) * | 2002-10-03 | 2012-04-05 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
| US7429603B2 (en) * | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
| US20050113566A1 (en) * | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
| WO2006047504A1 (en) * | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Aromatic amides as inhibitors of c-fms kinase |
| KR101443651B1 (ko) * | 2005-10-18 | 2014-09-23 | 얀센 파마슈티카 엔.브이. | Ｆｌｔ-3 키나제의 억제 방법 |
-
2005
- 2005-10-20 ES ES05815361.0T patent/ES2611604T3/es not_active Expired - Lifetime
- 2005-10-20 MX MX2007004784A patent/MX2007004784A/es active IP Right Grant
- 2005-10-20 UA UAA200704498A patent/UA88648C2/ru unknown
- 2005-10-20 HU HUE05815361A patent/HUE033089T2/en unknown
- 2005-10-20 CA CA2585053A patent/CA2585053C/en not_active Expired - Fee Related
- 2005-10-20 EP EP05815361.0A patent/EP1807077B1/en not_active Expired - Lifetime
- 2005-10-20 KR KR1020077011145A patent/KR101273434B1/ko not_active Expired - Fee Related
- 2005-10-20 CN CN2005800435040A patent/CN101437514B/zh not_active Expired - Fee Related
- 2005-10-20 AU AU2005299837A patent/AU2005299837A1/en not_active Abandoned
- 2005-10-20 EA EA200700918A patent/EA013250B1/ru not_active IP Right Cessation
- 2005-10-20 BR BRPI0516947-0A patent/BRPI0516947A/pt not_active Application Discontinuation
- 2005-10-20 WO PCT/US2005/037868 patent/WO2006047277A2/en not_active Ceased
- 2005-10-20 JP JP2007538060A patent/JP5046950B2/ja not_active Expired - Fee Related
- 2005-10-20 PT PT58153610T patent/PT1807077T/pt unknown
- 2005-10-20 PL PL05815361T patent/PL1807077T3/pl unknown
- 2005-10-20 DK DK05815361.0T patent/DK1807077T3/en active
-
2007
- 2007-05-15 NO NO20072489A patent/NO339555B1/no not_active IP Right Cessation
- 2007-05-21 ZA ZA200704106A patent/ZA200704106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1807077T3 (pl) | 2017-05-31 |
| EP1807077A4 (en) | 2011-09-21 |
| BRPI0516947A (pt) | 2008-09-23 |
| EP1807077B1 (en) | 2016-11-23 |
| CA2585053A1 (en) | 2006-05-04 |
| JP5046950B2 (ja) | 2012-10-10 |
| NO20072489L (no) | 2007-06-29 |
| EP1807077A2 (en) | 2007-07-18 |
| HUE033089T2 (en) | 2017-11-28 |
| WO2006047277A3 (en) | 2009-05-07 |
| PT1807077T (pt) | 2017-01-06 |
| KR20070085382A (ko) | 2007-08-27 |
| NO339555B1 (no) | 2017-01-02 |
| CN101437514A (zh) | 2009-05-20 |
| WO2006047277A2 (en) | 2006-05-04 |
| AU2005299837A1 (en) | 2006-05-04 |
| JP2008517926A (ja) | 2008-05-29 |
| CA2585053C (en) | 2011-07-12 |
| EA013250B1 (ru) | 2010-04-30 |
| UA88648C2 (en) | 2009-11-10 |
| KR101273434B1 (ko) | 2013-06-11 |
| EA200700918A1 (ru) | 2008-06-30 |
| ZA200704106B (en) | 2009-09-30 |
| ES2611604T3 (es) | 2017-05-09 |
| DK1807077T3 (en) | 2017-01-23 |
| MX2007004784A (es) | 2007-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101437514B (zh) | C-fms激酶抑制剂 | |
| CN106573915B (zh) | 针对布罗莫结构域有活性的化合物 | |
| RU2708690C2 (ru) | Производные тиено[2,3-c]пиранов в качестве cftr модуляторов | |
| US7645755B2 (en) | Inhibitors of c-fms kinase | |
| CN101511796B (zh) | 咪唑衍生物 | |
| JP2019112449A (ja) | 嚢胞性線維症を処置するための新規化合物およびこれらの医薬組成物 | |
| CN104812748B (zh) | 二氢吡唑gpr40调节剂 | |
| TW201620875A (zh) | 作為ｌｓｄ１抑制劑之環丙胺 | |
| CN1950351B (zh) | 适用作h3配体的3-或4-单取代酚及苯硫酚衍生物 | |
| CN110167935A (zh) | 作为αV整合素抑制剂的3-经取代的丙酸 | |
| CN102498107A (zh) | 作为激酶抑制剂的杂芳基化合物 | |
| CN101163675A (zh) | 含氮杂环化合物 | |
| CN101610768B (zh) | 抑制c kit激酶的方法 | |
| CN102471310A (zh) | 用于治疗增生性疾病的联吡啶化合物 | |
| CN119301096A (zh) | Myst家族赖氨酸乙酰转移酶的抑制剂 | |
| IL182735A (en) | C – fms kinase inhibitors | |
| TWI691332B (zh) | 噻唑烷酮化合物及其用途 | |
| CN101466686A (zh) | C-fms激酶抑制剂 | |
| AU2011203515B2 (en) | Inhibitors of c-fms kinase | |
| HK1109342A (en) | Inhibitors of c-fms kinase | |
| HK1109342B (en) | Inhibitors of c-fms kinase | |
| HK1100823B (en) | 3-or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| HK1129043A (en) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20211020 |